Skip to main content
SpringerLink
Log in

Complete Response to Full-Dose Sorafenib Treatment in an Elderly HCC Patient: a Case Report

  • Case Report
  • Published:
Journal of Gastrointestinal Cancer Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5

References

  1. European Association For The Study Of The Liver, European Organisation For Research And Treatment Of Cancer. EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma. J Hepatol. 2012;56:908–43.

    Article  Google Scholar 

  2. Germano D, Tinessa V, Barletta E, et al. Targeted therapy for advanced hepatocellular cancer in the elderly: focus on sorafenib. Drugs Aging. 2013;30:887–92.

    Article  CAS  PubMed  Google Scholar 

  3. Cabibbo G, Maida M, Cammà C, Craxì A. Is the efficacy of sorafenib treatment in patients with hepatocellular carcinoma affected by age? Expert Rev Anticancer Ther. 2013;13:1355–61.

    Article  CAS  PubMed  Google Scholar 

  4. Di Costanzo GG, Tortora R, De Luca M, et al. Impact of age on toxicity and efficacy of sorafenib-targeted therapy in cirrhotic patients with hepatocellular carcinoma. Med Oncol. 2013;30:446.

    Article  PubMed  Google Scholar 

  5. Jo M, Yasui K, Kirishima T, et al. Efficacy and safety of sorafenib in very elderly patients aged 80 years and older with advanced hepatocellular carcinoma. Hepatol Res, in press 2014.

  6. Montella L, Addeo R, Cennamo G, et al. Sorafenib in elderly patients with advanced hepatocellular carcinoma: a case series. Oncology. 2013;84:265–72.

    Article  CAS  PubMed  Google Scholar 

  7. Wong H, Tang YF, Yao TJ, et al. The outcomes and safety of single-agent sorafenib in the treatment of elderly patients with advanced hepatocellular carcinoma (HCC). Oncologist. 2011;16:1721–8.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  8. Dufour JF. Hepatocellular carcinoma. Sorafenib—for once age is not an issue. Nat Rev Gastroenterol Hepatol. 2014;11:273–4.

    Article  PubMed  Google Scholar 

  9. Mohile S, Dale W, Hurria A. Geriatric oncology research to improve clinical care. Nat Rev Clin Oncol. 2012;9:571–8.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  10. Bruix J, Raoul JL, Sherman M, et al. Efficacy and safety of sorafenib in patients with advanced hepatocellular carcinoma: subanalyses of a phase III trial. J Hepatol. 2012;57:821–9.

    Article  CAS  PubMed  Google Scholar 

  11. Cheng AL, Kang YK, Lin DY, et al. Sunitinib versus sorafenib in advanced hepatocellular cancer: results of a randomized phase III trial. J Clin Oncol. 2013;31:4067–75.

    Article  CAS  PubMed  Google Scholar 

  12. Shao YY, Shau WY, Chan SY, et al. Impact of hepatitis C virus etiology on the efficacy of sorafenib in advanced hepatocellular carcinoma: a meta-analysis of randomized clinical trials. Presented at ILCA 2014.

  13. Himmelsbach K, Sauter D, Baumert TF, et al. New aspects of an anti-tumour drug: sorafenib efficiently inhibits HCV replication. Gut. 2009;58:1644–53.

    Article  CAS  PubMed  Google Scholar 

  14. Inghilesi AL, Gallori D, Antonuzzo L, et al. Predictors of survival in patients with established cirrhosis and hepatocellular carcinoma treated with sorafenib. World J Gastroenterol. 2014;20:786–94.

    Article  PubMed Central  PubMed  Google Scholar 

  15. Personeni N, Bozzarelli S, Pressiani T, et al. Usefulness of alpha-fetoprotein response in patients treated with sorafenib for advanced hepatocellular carcinoma. J Hepatol. 2012;57(1):101–7.

    Article  CAS  PubMed  Google Scholar 

  16. Vincenzi B, Santini D, Russo A, et al. Early skin toxicity as a predictive factor for tumor control in hepatocellular carcinoma patients treated with sorafenib. Oncologist. 2010;15:85–92.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  17. Estfan B, Byrne M, Kim R. Sorafenib in advanced hepatocellular carcinoma: hypertension as a potential surrogate marker for efficacy. Am J Clin Oncol. 2013;36:319–24.

    Article  CAS  PubMed  Google Scholar 

  18. Reig M, Torres F, Rodriguez-Lope C, et al. Early dermatologic adverse events predict better outcome in HCC patients treated with sorafenib. J Hepatol. 2014;61:318–24.

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgments

The authors have no conflicts of interest directly relevant to this study. Editorial assistance for the preparation of this manuscript was provided by Luca Giacomelli, PhD; this assistance was funded by Bayer Italy.

Author information

Authors and Affiliations

  1. Ultrasound Unit for Infectious Diseases, AORN dei Colli, Naples, Italy

    G. de Stefano, V. Iodice & N. Farella

Authors
  1. G. de Stefano
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. V. Iodice
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. N. Farella
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to G. de Stefano.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

de Stefano, G., Iodice, V. & Farella, N. Complete Response to Full-Dose Sorafenib Treatment in an Elderly HCC Patient: a Case Report. J Gastrointest Canc 46, 430–433 (2015). https://doi.org/10.1007/s12029-015-9720-5

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12029-015-9720-5

Keywords

Search

Navigation